StockData
EoCene Ltd. logo

EoCene Ltd. (EOCN) company profile

EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 31, 2026Score 5/30
$2.46−0.07 (-2.77%)

Close on Nov 17, 2026Market cap $2.46MP/E –Yield –

About EoCene

Pharmaceutical Preparations, SIC 2834

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics. Its lead investigational candidate is Aramchol, a compound historically evaluated for the treatment of non-alcoholic steatohepatitis and liver fibrosis. The company is actively working to advance Aramchol into oncological indications outside of liver disorders. In addition, it seeks to broaden and diversify its product development pipeline by targeting innovative candidates for cardiometabolic diseases. Because Galmed remains in the clinical development stage without approved commercial therapies, it operates without conventional commercial end-customer sales and relies primarily on licensing agreements and research collaborations.

The company conducts its operations from the State of Israel, maintaining its principal executive offices and headquarters in Ramat Gan. Galmed operates as a development-stage biopharmaceutical enterprise with a small core team of executive management, carrying out research, preclinical, and clinical trial activities through relationships with specialized third-party service providers.

Summary of the business section of EoCene's latest annual report, written by StockData.

Company profile

Company

Legal name
EoCene Ltd.
Founded
2000
Headquarters
Ramat Gan, L3
Address
C/O Meitar Law Offices, 16 Abba Hillel Silver Rd. 5250608
Phone
97236938448
Employees
6, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Brightman Almagor Zohar & Co., Tel Aviv, Israel

Stock & identifiers

Ticker
EOCN
Former tickers
GLMD until Mar 31, 2026
Exchange
Nasdaq
IPO date
Mar 13, 2014
Shares outstanding
7M, Dec 31, 2025
Filer category
Non-accelerated filer
Stock splits
1-for-8 reverse, Aug 19, 2026; 1-for-12 reverse, Apr 2, 2025; 1-for-12 reverse, Aug 30, 2024; 1-for-15 reverse, May 15, 2023
SEC CIK
1595353
FIGI
BBG005ZD02W1
Share class FIGI
BBG005ZD02V2
EIN
98-1147233

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Allen BaharaffChief Executive Officer, Director100,018
Guy NehemyaChief Operating Officer25,000
Yohai StenzlerChief Accounting Officer25,000
Doron Leib CohenChief Financial Officer2,083
Brueck Liat NissimovChief Scientific Officer–
Amir PoshinskiDirector12,500
Carol L. BrosgartDirector–
Shmuel NirDirector12,500
David SidranskyDirector1,042

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 13, 2014
Offer price
$13.50
Securities offered
425,610
Gross proceeds
$5.75M
Exchange
Nasdaq
First trading day
Mar 13, 2014
First-day close
$14.31+6.0%
Lock-up ends (est.)
Sep 9, 2014

“The initial public offering price is $13.50 per Share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had six employees, of which three were full-time employees and three were part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?